Cancer pharmacogenetics: The move from pharmacokinetics to pharmacodynamics

Current Pharmacogenomics

Volumn 4, Issue 1, 2006, Pages 39-46

  Hoskins, J M ^a   McLeod, H L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Chemotherapy; Microsatellite instability; Polymorphism; Tandem repeat in the enhancer region (TSER)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CL 387785; DEBRISOQUINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; IRINOTECAN; ISONIAZID; MERCAPTOPURINE; PRIMAQUINE; PROTEIN TYROSINE KINASE INHIBITOR; SPARTEINE; SUXAMETHONIUM; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DEATH; CELL FUNCTION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIARRHEA; DNA REPAIR; DOWNSTREAM PROCESSING; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HEREDITY; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW; SLEEP APNEA SYNDROME; SOMATIC MUTATION;

EID: 33646152560     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016006776055400     Document Type: Review

References (67)

1. Amann, J.; Kalyankrishna, S.; Massion, P, P.; Ohm, J. E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; Kim, Y. H.; Pollack, J. R.; Yanagisawa, K.; Gazdar, A.; Minna, J. D.; Kurie, J. M. and Carbone, D. P. (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65, 226-235.
2. Barber, T. D.; Vogelstein, B.; Kinzler, K. W. and Velculescu, V. E. (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883.
3. Bertilsson, L.; Dengler, H. J.; Eichelbaum, M. and Schulz, H. U. (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur. J. Clin. Pharmacol. 17, 153-155.
4. Cappuzzo, F.; Hirsch, F. R.; Rossi, E.; Bartolini, S.; Ceresoli, G. L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Domenichini, I.; Ludovini, V.; Magrini, E.; Gregorc, V.; Doglioni, C.; Sidoni, A.; Tonato, M.; Franklin, W. A.; Crino, L.; Bunn, P. A., Jr. and Varella-Garcia, M. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655.
5. Chabot, G. G. (1997) Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet. 33, 245-259.
6. Diaz, L. A., Jr. (2005) The current clinical value of genomic instability. Semin. Cancer Biol. 15, 67-71.
7. Eichelbaum, M.; Baur, M. P.; Dengler, H. J.; Osikowska-Evers, B. O.; Tieves, G.; Zekorn, C. and Rittner, C. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br. J. Clin. Pharmacol. 23, 455-458.
8. Eichelbaum, M.: Spannbrucker, N.: Steincke, B. and Dengler, H. J. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16, 183-187.
9. Evans, D. A.; Mahgoub, A.; Sloan, T. P.; Idle, J. R. and Smith, R. L. (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 17, 102-105.
10. Evans, W. E. and Mcleod, H. L. (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549.
11. Evans, W. E. and Relling, M. V. (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468.
12. Fallik, D.; Borrini, F.; Boige, V.; Viguier, J.; Jacob, S.; Miquel, C.; Sabourin, J. C.; Ducreux, M. and Praz, F. (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 63, 5738-5744.
13. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P. and Baselga, J. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-2246.
14. Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16, 538-548.
15. Gonzalez, F. J.; Skoda, R. C.; Kimura, S.; Umeno, M.; Zanger, U. M.; Nebert, D. W.; Gelboin, H. V.; Hardwick, J. P. and Meyer, U. A. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442-446.
16. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N. and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
17. Gough, A. C.; Miles, J. S.; Spurr, N. K.; Moss, J. E.; Gaedigk, A.; Eichelbaum, M. and Wolf, C. R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347, 773-776.
18. Graziano, F.; Kawakami, K.; Watanabe, G.; Ruzzo, A.; Humar, B.; Santini, D.; Catalano, V.; Ficarelli, R.; Merriman, T.; Panunzi, S.; Testa, E.; Cascinu, S.; Bearzi, I.; Tonini, G. and Magnani, M. (2004) Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Int. J. Cancer 112, 1010-1014.
19. Horie, N.; Aiba, H.; Oguro, K.; Hojo, H. and Takeishi, K. (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197.
20. Huang, S. F.; Liu, H. P.; Li, L. H.; Ku, Y. C.; Fu, Y. N.; Tsai, H. Y.; Chen, Y. T.; Lin, Y. F.; Chang, W. C.; Kuo, H. P.; Wu, Y. C.; Chen, Y. R. and Tsai, S. F. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195-8203.
21. Iacopetta, B.; Grieu, F.; Joseph, D. and Elsaleh, H. (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85, 827-830.
22. Innocenti, F.; Undevia, S. D.; Iyer, L.; Chen, P. X.; Das, S.; Kocherginsky, M.; Karrison, T.; Janisch, L.; Ramirez, J.; Rudin, C. M.; Vokes, E. E. and Ratain, M. J. (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388.
23. Iyer, L.; Das, S.; Janisch, L.; Wen, M.; Ramirez, J.; Karrison, T.; Fleming, G. F.; Vokes, E. E.; Schilsky, R. L. and Ratain, M. J. (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47.
24. Kawakami, K.; Ishida, Y.; Danenberg, K. D.; Omura, K.; Watanabe, G. and Danenberg, P. V. (2002) Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity. Jpn. J. Cancer Res. 93, 1221-1229.
25. Kawakami, K.; Omura, K.; Kanehira, E. and Watanabe, Y. (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19, 3249-3252.
26. Kawakami, K. and Watanabe, G. (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63, 6004-6007.
27. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G. and Halmos, B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792.
28. Kosaka, T.; Yatabe, Y.; Endoh, H.; Kuwano, H.; Takahashi, T. and Mitsudomi, T. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64, 8919-8923.
29. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J. Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J. and Kay, A. C. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158.
30. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Nam, H. K.; Park, W. S.; Nam, S. W.; Kim, M. S.; Sun, D. I.; Lee, Y. S.; Jang, J. J.; Lee, J. Y.; Yoo, N. J. and Lee, S. H. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 2879-2882.
31. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Park, W. S.; Nam, S. W.; Lee, J. Y.; Yoo, N. J. and Lee, S. H. (2005) Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int. J. Cancer 113, 510-511.
32. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J. and Haber, D. A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
33. Mandola, M. V.; Stoehlmacher, J.; Muller-Weeks, S.; Cesarone, G.; Yu, M. C.; Lenz, H. J. and Ladner, R. D. (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63, 2898-2904.
34. Mandola, M. V.; Stoehlmacher, J.; Zhang, W.; Groshen, S.; Yu, M. C.; Iqbal, S.; Lenz, H. J. and Ladner, R. D. (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14, 319-327.
35. Marcuello, E.; Altes, A.; Menoyo, A.; Del Rio, E.; Gomez-Pardo, M. and Baiget, M. (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682.
36. Marie, Y.; Carpentier, A. F.; Omuro, A. M.; Sanson, M.; Thillet, J.; Hoang-Xuan, K. and Delattre, J. Y. (2005) EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64, 1444-1445.
37. Marsh, S.; Ameyaw, M. M.; Githang'a, J.; Indalo, A.; Ofori-Adjei, D. and Mcleod, H. L. (2000) Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 16, 528.
38. Marsh, S. and Mcleod, H. L. (2004) Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5, 835-843.
39. Meyer, U. A. (2004) Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5, 669-676.
40. Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T. and Yatabe, Y. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520.
41. Moroni, M.; Veronese, S.; Benvenuti, S.; Marrapese, G.; Sartore-Bianchi, A.; Di Nicolantonio, F.; Gambacorta, M.; Siena, S. and Bardelli, A. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286.
42. Nagahara, H.; Mimori, K.; Ohta, M.; Utsunomiya, T.; Inoue, H.; Barnard, G. F.; Ohira, M.; Hirakawa, K. and Mori, M. (2005) Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res. 11, 1368-1371.
43. Nicholson, R. I.; Gee, J. M. and Harper, M. E. (2001) EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl 4), S9-S15.
44. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E. and Meyerson, M. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
45. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G. and Varmus, H. (2005) Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Med. 2, e73.
46. Pavillard, V.; Agostini, C.; Richard, S.; Charasson, V.; Montaudon, D. and Robert, J. (2002) Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother. Pharmacol. 49, 329-335.
47. Perez-Soler, R. (2004) Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin. Lung Cancer 6(Suppl 1), S20-S23.
48. Petros, W. P. and Evans, W. E. (2004) Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol. Sci. 25, 457-464.
49. Phillips, K. A.; Veenstra, D.; Van Bebber, S. and Sakowski, J. (2003) An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 4, 231-239.
50. Pirmohamed, M. and Park, B. K. (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305.
51. Pullarkat, S. T.; Stoehlmacher, J.; Ghaderi, V.; Xiong, Y. P.; Ingles, S. A.; Sherrod, A.; Warren, R.; Tsao-Wei, D.; Groshen, S. and Lenz, H. J. (2001) Thymidylate synthase gene polymorphism, determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70.
52. Ribic, C. M.; Sargent, D. J.; Moore, M. J.; Thibodeau, S. N.; French, A. J.; Goldberg, R. M.; Hamilton, S. R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L. E.; Tu, D.; Redston, M. and Gallinger, S. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257.
53. Ritchie, J. C.; Crothers, M. J.; Shah, R. R.; Idle, J. R. and Smith, R. L. (1986) The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis. Xenobiotica 16, 503-509.
54. Rouits, E.; Boisdron-Celle, M.; Dumont, A.; Guerin, O.; Morel, A. and Gamelin, E. (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159.
55. Satoh, T.; Hosokawa, M.; Atsumi, R.; Suzuki, W.; Hakusui, H. and Nagai, E. (1994) Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 17, 662-664.
56. Shih, J. Y.; Gow, C. H. and Yang, P. C. (2005) EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N. Engl. J. Med. 353, 207-208.
57. Tamborini, E.; Bonadiman, L.; Greco, A.; Albertini, V.; Negri, T.; Gronchi, A.; Bertulli, R.; Colecchia, M.; Casali, P. G.; Pierotti, M. A. and Pilotti, S. (2004) A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127, 294-299.
58. Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; Da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J. and Shepherd, F. A. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144.
59. Tucker, G. (2004) Pharmacogenetics - expectations and reality. BMJ 329, 4-6.
60. Uchida, K.; Hayashi, K.; Kawakami, K.; Schneider, S.; Yochim, J. M.; Kuramochi, H.; Takasaki, K.; Danenberg, K. D. and Danenberg, P. V. (2004) Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin. Cancer Res. 10, 433-439.
61. Ulrich, C. M.; Bigler, J.; Velicer, C. M.; Greene, E. A.; Farin, F. M. and Potter, J. D. (2000) Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 9, 1381-1385.
62. Van Triest, B. and Peters, G. J. (1999) Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 57, 179-194.
63. Villafranca, E.; Okruzhnov, Y.; Dominguez, M. A.; Garcia-Foncillas, J.; Azinovic, I.; Martinez, E.; Illarramendi, J. J.; Arias, F.; Martinez Monge, R.; Salgado, E.; Angeletti, S. and Brugarolas, A. (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19, 1779-1786.
64. Vogel, F. (1959) Moderne probleme der humangenetik. Ergebnisse Inneren Medizin and Keinderheilkunde 12, 52-125.
65. Watanabe, T.; Wu, T. T.; Catalano, P. J.; Ueki, T.; Satriano, R.; Haller, D. G.; Benson, A. B., 3rd and Hamilton, S. R. (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344, 1196-1206.
66. Zanger, U. M.; Vilbois, F.; Hardwick, J. P. and Meyer, U. A. (1988) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27, 5447-5454.
67. Zinzindohoue, F.; Ferraz, J. M. and Laurent-Puig, P. (2001) Thymidylate synthase promoter polymorphism. J. Clin. Oncol. 19, 3442.